Navigation Links
Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
Date:10/19/2007

y assigned to either of the MIRCERA arms or to continue epoetin alfa or beta at their current dose and administration interval. Patients randomized to MIRCERA received a starting dose based on the previous weekly dose of epoetin.

In contrast to previous studies in which dialysis patients were converted from IV epoetin using sequential increases in dosing intervals, most patients in MAXIMA were converted directly from a predominantly three-times-a-week regimen of epoetin (87 percent of patients) to IV MIRCERA administered once every two weeks or once every four weeks.

MAXIMA Study Findings

The MAXIMA results showed:

-- Minute changes in Hb levels throughout the duration of the study (mean

changes from the baseline to the evaluation periods were -0.71, -0.25,

and -0.75 g/L in the MIRCERA once every two weeks; MIRCERA once every

four weeks and epoetin groups, respectively), illustrating that the

primary efficacy parameter (mean change in Hb level between baseline

and evaluation periods) was met.

-- For the secondary analysis, the proportion of patients maintaining a

mean Hb within plus or minus 10 g/L of baseline was 68 percent, 68

percent, and 67 percent in the MIRCERA once every two weeks and MIRCERA

once every four weeks and epoetin groups, respectively.

-- The most common serious adverse events in the three groups were sepsis,

pneumonia and arteriograft thrombosis. A similar incidence of adverse

events occurred across all treatment arms with the most frequent

adverse events mild to moderate and had a distribution typical for this

patient population.

About MIRCERA

The clinical program for MIRCERA consisted of 10 global studies involving more than 2,700 patients from 29 countries. The Phase III program for MIRCERA included two correction studies and four maintenance studies exploring intravenous (IV) and subcuta
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014 ... industry leader in bioactive lipid-targeted therapeutics, received official notification ... has been granted another key patent supporting its ... newly issued patent, European patent No. 2087002, claims ... substance in Lpath,s two lead compounds, iSONEP and ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/20/2014)... N.C., Oct. 20, 2014  BioPontis Alliance for ... both philanthropies, announced today the creation of a ... treatment of the rare disease known as Charcot- ... its alliance model earlier this month. Today,s partnership ... a collaborative model where researchers and all CMT ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... On July 31 , Massachusetts lawmakers passed legislation ... sentencing laws. , , , ... Drug offenders serving mandatory minimum sentences at county Houses of Correction will ... bill lawmakers voted on did not include two reforms previously endorsed by ...
... Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals ... a privately-held drug development company focused on liver disease and oncology. ... Conatus Pharmaceuticals ... of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The ...
Cached Medicine Technology:FAMM Applauds Massachusetts Legislature for Sentencing Reforms 2Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground on ... $11 million project will include the latest in Assisted ... full-service restaurant style dining. , “We are excited to ... Living apartments,” said Kara Hanzie, Rockynol Executive Director during ... care and this investment is proof of our commitment.” ...
(Date:10/20/2014)... 20, 2014 Final Cut Pro X Plugin ... the Citrus theme for FCPX filmmakers . , “Fun, ... describe the Citrus theme” Says Christina Austin, CEO of Pixel ... so professional.” , Citrus comes with all the tools needed ... are: four transitions for added style, a title screen for ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most ... range of bamboo deckings . Moreover, the company ... they are now available at deeply discounted rates. ... hard to overstate the significance of online business nowadays. ... services. The company’s workers are striving to deliver both ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... Leading Researchers to Discuss, State of Breast Cancer ... BOSTON, April 9 The Massachusetts Affiliate of Susan ... 10 at Harvard Medical,School, featuring some of the nation,s ... recent advances in breast,cancer research and the need for ...
... April 9, 2008 A company founded by an,industry ... and Canada sales,and distribution outlet for the Japanese "Paro" ... (ISC) of Japan, announced,today at the RoboBusiness Conference & ... Inc., founded by Walter Weisel, began its development,through a ...
... global clinical,research organization, is pleased to announce that it ... CRO,s in Las Vegas, Nevada from April,14 to the ... of its executive team and employees. Chiltern will be ... at 2:45 pm -- Track: Relationship Management Resource ...
... suggests that a genetic fingerprint associated with normal embryonic ... function of cancer stem cells. The research, published by ... Stem Cell, demonstrates that embryonic stem cells and multiple ... pattern that is repressed in normal differentiated cells, a ...
... ability to stabilize blood-brain barrier may play role in ... A little caffeine every day could offer some protection ... , Rabbits given the daily caffeine equivalent of one ... 12 weeks suffered relatively little damage in their blood-brain ...
... (MDC), a privately-owned chain of dental clinics in ... Dental Center, has reached,a settlement with the United ... allegations, the Justice Department announced today. Under the,agreement, ... that it,caused false or fraudulent claims for payment ...
Cached Medicine News:Health News:Massachusetts Affiliate of Susan G. Komen for the Cure to Spotlight Gaps in Breast Cancer Research 2Health News:'Paro,' the Baby Seal Service Robot From Japan, Finds a New Home in the United States With Help From JETRO 2Health News:Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008. 2Health News:Module map links embryonic stem cells and cancer stem cells 2Health News:Caffeine May Block High Cholesterol Linked to Alzheimer's 2Health News:North Carolina Dental Services Chain Pays $10 Million to Resolve False Claims Allegations 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: